# Alaunos Therapeutics, Inc.: overview TCRT · Nasdaq · CIK 1107421 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tcrt.md) · [Financials](/companies/tcrt/financials.md) · [Filings](/companies/tcrt/filings.md) · [Insiders](/companies/tcrt/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-352421.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-352421). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001193125-25-282988.md) | [4.0 d](/filings/0001193125-26-134720.md) | [2.0](/filings/0001193125-26-227272.md) | [0.0](/filings/0001193125-26-352421.md) | [0.0](/filings/0001193125-25-282988.md) | [3.0 d](/filings/0001193125-26-134720.md) | [0.0](/filings/0001193125-26-227272.md) | [0.0](/filings/0001193125-26-352421.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(18875.0%) d](/filings/0001193125-26-134720.md) | [(54600.0%)](/filings/0001193125-26-227272.md) | not reported | not reported | [(30233.3%) d](/filings/0001193125-26-134720.md) | not reported | not reported | | Net margin | % | not reported | [(18550.0%) d](/filings/0001193125-26-134720.md) | [(53650.0%)](/filings/0001193125-26-227272.md) | not reported | not reported | [(29766.7%) d](/filings/0001193125-26-134720.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.70)](/filings/0001193125-25-282988.md) | not reported | [(0.67)](/filings/0001193125-26-227272.md) | [(0.63)](/filings/0001193125-26-352421.md) | [(0.55)](/filings/0001193125-25-282988.md) | not reported | [(0.59)](/filings/0001193125-26-227272.md) | [(0.41)](/filings/0001193125-26-352421.md) | | Free cash flow | $k | [(781) d](/filings/0001193125-25-282988.md) | [(592) d](/filings/0001193125-26-134720.md) | not reported | not reported | not reported | [(553) d](/filings/0001193125-26-134720.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.4](/filings/0000950170-23-006377.md) | [2.9](/filings/0000950170-24-038868.md) | [0.0](/filings/0000950170-25-047758.md) | [0.0](/filings/0001193125-26-134720.md) | [0.0](/filings/0001193125-26-134720.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(19484.7%)](/filings/0000950170-23-006377.md) | [(1201.4%)](/filings/0000950170-24-038868.md) | [(685340.0%)](/filings/0000950170-25-047758.md) | [(48120.0%)](/filings/0001193125-26-134720.md) | [(84500.0%)](/filings/0001193125-26-134720.md) | | Net margin | % | [(19786.7%)](/filings/0000950170-23-006377.md) | [(1291.2%)](/filings/0000950170-24-038868.md) | [(93580.0%)](/filings/0001193125-26-134720.md) | [(46790.0%)](/filings/0001193125-26-134720.md) | [(83520.0%)](/filings/0001193125-26-134720.md) | | Diluted EPS | $ per share | [(0.37)](/filings/0000950170-23-006377.md) | [(2.61)](/filings/0000950170-24-038868.md) | [(21.97)](/filings/0000950170-25-047758.md) | [(2.92)](/filings/0001193125-26-134720.md) | [(2.20)](/filings/0001193125-26-134720.md) | | Free cash flow | $m | [(64.8)](/filings/0000950170-23-006377.md) | [(29.4)](/filings/0000950170-24-038868.md) | [(30.3)](/filings/0000950170-25-047758.md) | [(5.0)](/filings/0001193125-26-134720.md) | [(3.0)](/filings/0001193125-26-134720.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tcrt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $48.3k | 21,353 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $43.8k | 19,356 | | Reduced −3,204 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $35.0k | 15,497 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $31.8k | 14,063 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $26.8k | 11,870 | | Added +1,351 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $3.9k | 1,731 | | Reduced −48 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $3.7k | 1,621 | | Added +38 | | [Arax Advisory Partners](/funds/1586767.md) | 2026-06-30 | $2.7k | 1,216 | | New +1,216 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $2.2k | 992 | | Reduced −1,282 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.9k | 836 | | Added +183 | ## Recent filings [All 1,067 filings](/companies/tcrt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 16:30 ET | [8-K](/filings/0001193125-26-430507.md) | 8.01 Other events | 0001193125-26-430507 | | 2026-10-21 | 20:30 ET | [8-K](/filings/0001193125-26-427890.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001193125-26-427890 | | 2026-10-15 | 23:55 ET | [SCHEDULE 13D/A](/filings/0001193805-26-001370.md) | Ownership report, active investor, amended | 0001193805-26-001370 | | 2026-10-15 | 20:01 ET | [SCHEDULE 13D](/filings/0001683168-26-007898.md) | Ownership report, active investor | 0001683168-26-007898 | | 2026-10-13 | 13:28 ET | [8-K](/filings/0001193125-26-419829.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-419829 | | 2026-10-09 | 20:30 ET | [8-K](/filings/0001193125-26-419154.md) | 3.01 Delisting notice | 0001193125-26-419154 | | 2026-09-22 | 20:30 ET | [8-K](/filings/0001193125-26-397996.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-397996 | | 2026-09-17 | 01:03 ET | [8-K](/filings/0001193125-26-393462.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws | 0001193125-26-393462 | | 2026-08-14 | 20:31 ET | [10-Q](/filings/0001193125-26-352421.md) | Quarterly report, period 2026-06-30 | 0001193125-26-352421 | | 2026-06-29 | 12:30 ET | [8-K](/filings/0001193125-26-286914.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-286914 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-134720.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d52b4603-e5d9-4b1d-97ed-ef2828e03f1f) ## About the filer - CIK: 1107421 - Tickers: TCRT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.